CAR-T treatment for CD70-positive advanced solid tumors
Treatments studied
Part of Cancer, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a lab-made immune therapy (CAR-T) that targets a protein called CD70 found on some advanced cancers. It’s designed for people whose solid tumors have spread and no standard treatments have worked or weren’t tolerated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older, and your cancer is an advanced or metastatic solid tumor
- Your tumor must test positive for CD70 (specifically IHC 3+) on a tumor sample
- You have tried standard treatments (like surgery/chemo/radiation/targeted therapy) and the cancer has grown or you couldn’t tolerate them
- You must have at least one measurable tumor area on scans and no local treatment to that area recently
- Your general performance is fairly good (ECOG 0 to 2) and you’re expected to live more than 12 weeks
- Your blood counts, heart, kidneys, liver, and oxygen levels must be within study limits, and you must be able to have cell collection (apheresis)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CAR-T cells that target a protein called CD70 found on some gynecologic cancer cells. It is for people whose cancer has advanced or spread and has not responded to or stopped responding to standard treatments.
This trial tests a new type of cell therapy called UCAR-T that targets a protein (CD70) found on many solid tumors. If you have advanced cancer that has not responded to standard treatments tricks and your tumor makes CD70, this experimental treatment may be an option.
This phase 1 trial tests a new way to use your own immune cells to fight advanced solid tumors. The treatment is given directly into the tumor. It is for people who have run out of standard treatment options.
This trial tests a personalized immune-cell treatment (CAR T) built from your own blood lymphocytes. It targets cancers that show a marker called CD70, aiming to slow or stop the cancer when other treatments didn’t work.
This trial tests a new type of immunotherapy called CAR-T cells for advanced ovarian, uterine, or other gynecological cancers that have not responded to standard treatments. The CAR-T cells are specially designed to target proteins (MUC1, MSLN, PD-L1) found on cancer cells.
This trial tests a new type of 'fast CAR-T' cell therapy for people with advanced solid tumors that have not been helped by standard treatments. CAR-T cells are a kind of immune cell that is reprogrammed to attack cancer cells that carry certain markers called mesothelin, MUC1, and PD-L1.
Hear when a new Metastatic Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.